Accepted Manuscript

Size and Growth Assessment of Pulmonary Nodules: Consequences of the Rounding

Kunwei Li, Rowena Yip, Ricardo Avila, Claudia I. Henschke, David F. Yankelevitz

PII: S1556-0864(16)33579-1

DOI: 10.1016/j.jtho.2016.12.010

Reference: JTHO 457

To appear in: Journal of Thoracic Oncology

Received Date: 10 September 2016
Revised Date: 28 November 2016
Accepted Date: 6 December 2016

Please cite this article as: Li K, Yip R, Avila R, Henschke CI, Yankelevitz DF, Size and Growth Assessment of Pulmonary Nodules: Consequences of the Rounding, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2016.12.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Size and Growth Assessment of Pulmonary Nodules: Consequences of the Rounding

Kunwei Li^{1,2}, Rowena Yip¹, Ricardo Avila³, Claudia I Henschke¹, David F. Yankelevitz¹

¹Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY

²Department of Radiology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China

³Accumetra, LLC

Corresponding author:

Claudia I. Henschke, Ph.D, M.D

Department of Radiology

Mount Sinai School of Medicine

1 Gustave Levy Place

New York, New York 10029

Tel: 212-241-2821

Fax: 212-241-9655

Email: Claudia. Henschke@mountsinai.org

Conflict of interest:

Dr. Yankelevitz is a named inventor on a number of patents and patent applications

relating to the evaluation of diseases of the chest including measurement of nodules.

Some of these, which are owned by Cornell Research Foundation (CRF), are non-

exclusively licensed to General Electric. As an inventor of these patents, Dr. Yankelevitz

is entitled to a share of any compensation which CRF may receive from its

commercialization of these patents. He is also an equity owner in Accumetra, a privately

1

Download English Version:

https://daneshyari.com/en/article/5701605

Download Persian Version:

https://daneshyari.com/article/5701605

<u>Daneshyari.com</u>